arrow
Y

Yiling Liu

yangtze university
H指数:20
被引数:2,308

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

tislelizumab联合化疗治疗转移性三阴性乳腺癌的最佳反应: 病例报告和文献复习

2024-03-280
OAAI
Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

阿来替尼治疗ALK阳性非小细胞肺癌的疗效与安全性及用于预测预后与疗效的血液标志物:一项回顾性队列研究

2022-12-015
OAAI
Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant

发现六氢呋喃 [3,2-b] 呋喃作为新的激酶选择性和口服生物可利用的JAK3抑制剂,用于治疗携带JAK3激活突变体的白血病

2022-07-214
PRE
Ovarian Cancer Population Screening and Mortality After Long-Term Follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A Randomised Controlled Trial

英国卵巢癌筛查合作试验 (UKCTOCS) 长期随访后的卵巢癌人群筛查和死亡率: 一项随机对照试验

2021-09-013
OA
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

英国卵巢癌筛查合作试验 (UKCTOCS) 长期随访后的卵巢癌人群筛查和死亡率: 一项随机对照试验

LANCET
IF88.5
2021-06-01387
OAAI
Dysregulated transcriptional responses to SARS-CoV-2 in the periphery
2021-02-1769
OAAI